Anti-Viral Drug Therapy Market Definition
The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. The anti-viral drug therapy industry includes establishments that manufacture anti-viral drugs, which are used to treat diseases or illnesses caused by viral infections. Examples of antiviral drugs include idoxuridine, famiciclovir, cidofovir, amantadine, zanamivir, tenofovir, adefovir and ribavirin.
Viruses are infective agents comprising of a core of nucleic acids, either RNA or DNA, and are surrounded by a layer of protein. These are not living organisms, and can reproduce only inside a living cell. Anti-viral drugs decrease the ability of viruses to reproduce. These drugs enter the cells infected with virus, and interfere with the ability of the virus to bind to the cell, and stimulate the immune system of the host.
Anti-Viral Drug Therapy Market Size
The global anti-viral drug therapy market reached a value of nearly $46,456.4 million in 2019, having increased at a compound annual growth rate (CAGR) of 5.0% since 2015. The market is expected to grow from $46,456.4 million in 2019 to $ 61,571.9 million in 2020 at a rate of 32.5%. The growth is mainly due to the increase in number of COVID-19 cases. The market is then expected to grow at a CAGR of 8.3% from 2021 and reach $74,385.9 million in 2023. The market is expected to reach $ 87,230.5 million in 2025, and $ 130,125.3 million in 2030.
Growth in the historic period resulted from rise in incidence of viral diseases, rapid growth in elderly population and strong economic growth. Factors that negatively affected growth of the market include patent expiration and increased pricing pressures. Going forward, rising number of COVID-19 cases and development of drug discovery procedures will positively affect the market. Factors that could hinder the growth of the anti-viral drug therapy market in the future include COVID-19 pandemic and shortage of supply of anti-viral drugs.
Anti-Viral Drug Therapy Market Drivers
The key drivers of the anti-viral drug therapy market include:
Developments In Drug Discovery Procedures
The anti-viral drug therapy market is expected to benefit from the latest developments in drug discovery procedures such as stem cells and organ-on-chip (OOC) technologies. OOCs are micro-engineered biometric systems that simulate the activities, mechanics and physiological responses of organ systems. Drug trial processes such as target identification, validation, and screening are being executed through OOC and stem cell technologies. These technologies are considerably reducing the drug discovery costs and generating reliable predictions on drug efficiency and human safety. Another area of development is physiology-simulation modelling, in which the integrated physiology of the human organism, in both health and disease, is simulated through a computer program. Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early stages of the drug discovery process that are operational within hours, whereas traditional models take weeks to conduct simulations. The wide adoption of these technologies is expected to drive the anti-viral drug therapy market in the forecast period.
Anti-Viral Drug Therapy Market Restraints
The key restraints on the anti-viral drug therapy market include:
Supply Shortages Of Anti-Viral Drugs
Due to COVID-19 pandemic, there are shortages in supply of anti-viral drugs which is expected to restrain the market in the forecast period. As there are no particular drugs available to treat COVID-19, doctors and physicians are prescribing existing anti-viral drugs in the treatment of COVID-19. Anti-viral drug supply shortage aroused due to a drastic increase in the number of COVID-19 cases across the world. For instance, in July 2020, there was a shortage of the Remdesivir drug which is an antiviral drug?developed by Gilead Sciences Inc and was in high demand for the treatment of COVID-19.
Anti-Viral Drug Therapy Market Trends
Major trends influencing the anti-viral drug therapy market include:
Combination Drug Therapy For Viral Diseases
Companies in the anti-viral drug therapy market are increasingly focusing on development and launch of combination drug therapy for treating HIV and other viral infections. Combination therapy involves the formulation of different drugs for treating different diseases. Combination therapy for treating viral infections has been proved effective in suppressing the replication of viruses and reducing antiviral resistance. In December 2019, Hetero, an India based pharmaceutical company launched an anti-retroviral combination drug consisting combination of drugs including Bictegravir (50mg), Emtricitabine (200mg), and Tenofovir Alafenamide (25mg) for treating patients with HIV. Also, in May 2020, a combination drug dose of Lopinavir/ritonavir which is already approved for treating HIV infection was approved for treating patients with COVID-19 by the Indian Council of Medical Research, India.
Global Research Initiatives And Funding
Pharmaceutical companies and federal governments are increasingly working together in partnerships and collaborations to provide funding and implement incentive programs for the research and development (R&D) of anti-viral drugs. These partnerships provide financial and technical assistance across different clinical development phases to pharmaceutical companies. For instance, in July 2020, pharmaceutical companies like Novavax and Regeneron received $2 billion funding from US federal government to manufacture drugs and vaccine against COVID-19. The Bill and Melinda Gates foundation with recipients including WHO, drug companies and governments together funded $125 million for drug development against COVID-19.
Opportunities And Recommendations In The Anti-Viral Drug Therapy Market
Opportunities – The top opportunities in the anti-viral drug therapy market segmented by drug class will arise in the reverse transcriptase inhibitors market segment, which will gain $24,880.4 million of global annual sales by 2023. The top opportunities in the anti-viral drug therapy market segmented by application will arise in the HIV segment, which will gain $ 10,038.8 million of global annual sales by 2023.
Recommendation – To take advantage of the opportunities, the business research company recommends the anti-viral drug therapy companies to focus on combination drug therapies, invest in 3D bioprinting technology, focus on R&D investments and research collaborations, focus on increasing production temporarily during the covid-19 pandemic, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, provide premium pricing for branded drugs, focus on increasing awareness on importance of healthcare, advising asthmatics to use preventive medication to protect against covid-19, focus on educating the people on vaccines and focus on developing generics drugs.
Anti-Viral Drug Therapy Market Segmentation
The anti-viral drug therapy market is segmented by drug class and application.
By Drug Class
The anti-viral drug therapy market can be segmented by drug class into
Reverse transcriptase inhibitors market was the largest segment of the anti-viral drug therapy market segmented by drug class, accounting for 50.0% of the total in 2019. Also, it is expected to be the fastest growing segment in the anti-viral drug therapy market segmented by drug class, at a CAGR of 20.0% during 2019-2023.
- a. DNA (Nucleotide) Polymerase Inhibitors
- b. Reverse Transcriptase Inhibitors
- c. Protease Inhibitors
- d. Neuraminidase Inhibitors
- e. Others
The anti-viral drug therapy market can be segmented by application into
The HIV market was the largest segment of the anti-viral drug therapy market segmented by application, accounting for 34.1% of the total in 2019. Going forward, the influenza segment is expected to be the fastest growing segment in the anti-viral drug therapy market segmented by application, at a CAGR of 14.5% during 2019-2023.
- a. HIV
- b. Hepatitis
- c. Herpes
- d. Influenza
- e. Others
The anti-viral drug therapy is segmented by geography into
North America was the largest region in the global anti-viral drug therapy market, accounting for 50.6% of the total in 2019. It was followed by Asia Pacific and Western Europe, and then the other regions. Going forward, the fastest-growing regions in the anti-viral drug therapy market will be Asia Pacific and Africa, where growth will be at CAGRs of 14.7% and 13.8% respectively. These will be followed by Middle East and North America, where the markets are expected to grow at CAGRs of 13.7% and 12.3% respectively.
- o Asia Pacific
- South Korea
- o Western Europe
- o Eastern Europe
- o North America
- o South America
- o Middle East
- o Africa
Anti-Viral Drug Therapy Competitive Landscape
Major Competitors are:
- • Gilead Sciences Inc
- • GlaxoSmithKline plc
- • Johnson & Johnson
- • AbbVie Inc.
- • Merck & Co., Inc.
Other Competitors Include:
- • Bristol-Myers-Squibb
- • Boehringer Ingelheim
- • Aurobindo Pharma
- • Dr. Reddy’s Laboratories Ltd
- • Cipla Inc
- • Hanmi Pharmaceutical
- • KYORIN Holdings, Inc.
- • Daewoong Pharmaceutical Co.,Ltd
- • Shanghai Pharmaceuticals
- • Fosun Pharma
- • Yangtze River Pharmaceutical Group
- • Jiangsu Hengrui Medicine Co., Ltd
- • Harbin Pharmaceutical Group
- • Xian-Janssen Pharmaceutical Ltd
- • Sinopharm Group
- • Shanghai Acebright Pharmaceuticals Group Co., Ltd.
- • Guangzhou Pharmaceutical Company Limited
- • China Meheco
- • CSPC Pharmaceutical
- • Sun Pharma
- • Lupin Limited
- • Zydus Cadila
- • Intas Pharmaceuticals
- • Strides Pharma
- • Divis Laboratories
- • Alkem Laboratories
- • Glenmark Pharmaceuticals
- • Takeda Pharmaceutical Company
- • Otsuka Pharmaceutical
- • Daiichi Sankyo
- • Nichi-Iko Pharmaceutical Co., Ltd
- • Chugai Pharmaceutical Co.
- • Astellas Pharma
- • Mitsubishi Tanabe Pharma
- • Sumitomo Dainippon Pharma
- • Eisai
- • Shionogi Co.Ltd.
- • Teva UK Limited
- • AstraZeneca
- • Abbott Laboratories
- • Vectura Group
- • Novartis AG
- • Roche Holding AG
- • Pfizer
- • Hikma Pharmaceuticals
- • Sanofi
- • Pharmstandard
- • Pharmasyntez
- • R-Pharm
- • Alium
- • ChemRar Group
- • Servier
- • Johnson & Johnson
- • Novo Nordisk
- • BioCryst Pharmaceuticals Inc.
- • Selva Therapeutics
- • Atea Pharmaceuticals
- • Emergent BioSolutions
- • Apotex
- • EMS Pharma
- • Hypermarcas
- • Medley
- • Ache
- • Eurofarma
- • Teuto Brasileiro
- • Biolab Farmaceutica
- • Cristalia
- • Libbs
- • União Quimica
- • Saudi Pharmaceutical Industries
- • Medical Appliances Corporation (SPIMACO)
- • Gulf Pharmaceutical Industries (Julphar)
- • Mylan Laboratories
- • BMS
- • Ascedis Health